{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:07:34Z","timestamp":1779134854657,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.athoracsur.2020.12.004","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T17:55:39Z","timestamp":1608832539000},"page":"1862-1869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura"],"prefix":"10.1016","volume":"112","author":[{"given":"Luis F.","family":"Tapias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Mino-Kenudson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Choy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Muniappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning A.","family":"Gaissert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald C.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Mathisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lanuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2020.12.004_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/LMT.15.19","article-title":"Solitary fibrous tumors of the pleura: review of literature with up-to-date observations","volume":"4","author":"Tapias","year":"2015","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.athoracsur.2012.04.028","article-title":"Solitary fibrous tumor of the pleura: outcomes of 157 complete resections in a single center","volume":"94","author":"Lahon","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ejcts\/ezs629","article-title":"Risk factor analysis for the recurrence of resected solitary fibrous tumours of the pleura: a 33-year experience and proposal for a scoring system","volume":"44","author":"Tapias","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JTO.0000000000000401","article-title":"Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting","volume":"10","author":"Bylicki","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ctrv.2018.02.002","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions","volume":"64","author":"Remon","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1159\/000484041","article-title":"Durable near-complete response to anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura","volume":"10","author":"Boothe","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib9","series-title":"IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer","year":"2017"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jtho.2016.08.134","article-title":"Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment","volume":"11","author":"Huynh","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1378\/chest.14-1180","article-title":"Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura","volume":"147","author":"Tapias","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ejca.2013.03.017","article-title":"Response to chemotherapy of solitary fibrous tumour: a retrospective study","volume":"49","author":"Stacchiotti","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-3329-3-7","article-title":"The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis","volume":"3","author":"Park","year":"2013","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib14","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1002\/cncr.26098","article-title":"Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor","volume":"117","author":"Park","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib15","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1093\/annonc\/mds143","article-title":"Sunitinib malate in solitary fibrous tumor (SFT)","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib16","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s10637-013-0023-z","article-title":"Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF\/GETO)","volume":"31","author":"Valentin","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jtho.2018.05.040","article-title":"Comparison of risk stratification models to predict recurrence and survival in pleuropulmonary solitary fibrous tumor","volume":"13","author":"Reisenauer","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11060-018-2876-7","article-title":"Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor\/hemangiopericytoma","volume":"139","author":"Kamamoto","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D\u2019Angelo","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib21","first-page":"192","article-title":"Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors","volume":"33","author":"K\u00f6semehmeto\u011flu","year":"2017","journal-title":"Turk Patoloji Derg"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib22","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib23","article-title":"TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma","volume":"3","author":"Leduc","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib24","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.athoracsur.2020.12.004_bib27","first-page":"1","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497520321317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497520321317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T04:11:06Z","timestamp":1757736666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497520321317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0003497520321317"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2020.12.004","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2020.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Society of Thoracic Surgeons Published by Elsevier","name":"copyright","label":"Copyright"}]}}